Navigation Links
Vermillion Announces Issuance of Patent for Alzheimer's Disease Diagnosis

FREMONT, Calif., June 29 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Pink Sheets: VRML), a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Biomarkers for Alzheimer's disease" to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of Alzheimer's disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay.

"The granting of our Alzheimer's disease biomarker patent is additional validation of our approach to intellectual property protection. We view the increasing breadth of our patent portfolio as a significant corporate asset," said Gail S. Page, CEO and Chairperson.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California. Additional information about Vermillion can be found on the Web at

About OVA1™

OVA1(TM) is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers - Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), beta 2-Microglobulin (beta 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) - and a proprietary FDA-cleared software device to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned. OVA1™ is a trademark of Vermillion Inc.

Forward-Looking Statement

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. There are no guarantees that Vermillion will succeed in its efforts to commercialize ovarian cancer or OVA1™ diagnostics products in 2010 or during any other period of time. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty in obtaining intellectual property protection for inventions made by Vermillion; (2) unproven ability of Vermillion to develop, and commercialize diagnostic products based on findings from its disease association studies; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of market acceptance of its OVA1™ diagnostic test or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payers such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid or Vermillion will be able to relist its shares on the NASDAQ Global Market or on other national securities exchange; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law. In addition, any financial information presented in this press release is unaudited and subject to adjustment following Vermillion's internal review and quarterly processes as well as annual audit.

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Receives Award From the Society of Gynecologic Oncologists
2. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
3. Vermillion and the Ohio State University Report That Novel Diagnostic Test May Help Predict Risk for Relapse of TTP, A Serious Blood Disorder
4. Vermillion Files 510(k) Application With U.S. Food & Drug Administration for OVA1 Ovarian Tumor Triage Test
5. Vermillion Renews Strategic Alliance Agreement With Quest Diagnostics, Inc.
6. Vermillion Presents Critical Data From Its OVA1 Clinical Trial
7. Vermillion Announces the Reappointment of Officers and Confirmation of Director
8. Vermillion to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
9. Vermillion Announces $43.05 Million Private Placement of Common Stock
10. Vermillion Files Plan of Reorganization
11. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
Post Your Comments:
(Date:11/27/2015)... Research and Markets ( ) has announced the ... report to their offering. ... author the present scenario and growth prospects of the ... market size, the report considers revenue generated from the ... copper IUDs. The report forecasts the global intrauterine devices ...
(Date:11/26/2015)... November 26, 2015 Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... la inmunoterapia con la terapia fotodinámica de Bremachlorin para ... Research . --> Clinical Cancer Research . ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... 29, 2015 , ... "I struggled for years with pain every day. I ... would love to do, I missed. We moved back home from living out of ... first. They have changed my life drastically. I love all of the people involved ...
(Date:11/29/2015)... ... , ... NewsWatch featured X-wing as part of its monthly Tech Report, which ... expert and special reporter for NewsWatch, conducted the review and shared with viewers how ... future because flying cars are about to become a reality. Where’s the idea from? ...
(Date:11/29/2015)... ... ... While conventional walkers afford considerable help with mobility, their design does not allow ... from Uniontown, Pa., has found a way to address those needs. , He developed ... to improve the user’s quality of life. To begin with, this improved mobility aid ...
(Date:11/29/2015)... ... November 29, 2015 , ... ProStatic ... distortion effect tool designed specially for Final Cut Pro X. FCPX ... with the easy-to-use modification controls. Destoying and creating chaotic distortion is now quick ...
(Date:11/29/2015)... ... November 29, 2015 , ... Key Housing, a top-rated ... announce their December, 2015, featured apartment community: Epic. In showcasing this featured apartment community ... the tight Bay Area rental market to efficiently find housing suitable to their needs ...
Breaking Medicine News(10 mins):